IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in IN8BIO, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- +1 vs. Q4 2022
- Shares held
- 1.37M
- +157.7K (+13.0%) vs. Q4 2022
- Total value
- $1.78M
- −$1.02M (−36.4%) vs. Q4 2022
- New holders
- 1
- 6 more added
- Sold out
- 0
- 3 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INAB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 21 | $5.35M |
| Q1 2026 | 19 | $5.55M |
| Q4 2025 | 22 | $7.45M |
| Q3 2025 | 19 | $2.13M |
| Q2 2025 | 12 | $1.83M |
| Q1 2025 | 28 | $3.60M |
| Q4 2024 | 26 | $7.72M |
| Q3 2024 | 26 | $2.06M |
| Q2 2024 | 26 | $6.77M |
| Q1 2024 | 32 | $10.2M |
| Q4 2023 | 30 | $11.4M |
| Q3 2023 | 21 | $2.58M |
| Q2 2023 | 22 | $3.59M |
| Q1 2023 | 17 | $1.78M |
| Q4 2022 | 16 | $2.79M |
| Q3 2022 | 17 | $2.42M |
| Q2 2022 | 15 | $5.50M |
| Q1 2022 | 14 | $7.02M |
| Q4 2021 | 14 | $7.80M |
| Q3 2021 | 13 | $12.2M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding IN8BIO, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 46 | $0 | 0.00% | +46 | New |
| Bank of America Corp | 38 | $50 | 0.00% | +18+90.0% | Added |
| UBS Group AG | 3,133 | $4.07K | 0.00% | −327−9.5% | Reduced |
| Tower Research Capital LLC (TRC) | 4,884 | $6.00K | 0.00% | −1,788−26.8% | Reduced |
| HighTower Advisors, LLC | 10,000 | $13.0K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 10,126 | $13.2K | 0.00% | +20.0% | Added |
| Northern Trust Corp | 13,253 | $17.2K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 24,482 | $31.8K | 0.00% | +13,329+119.5% | Added |
| BlackRock Inc. | 32,599 | $42.4K | 0.00% | +1,068+3.4% | Added |
| Geode Capital Management, LLC | 57,846 | $75.2K | 0.00% | −819−1.4% | Reduced |
| Ensign Peak Advisors, Inc | 70,028 | $91.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 74,000 | $96.2K | 0.00% | 00.0% | Unchanged |
| Rock Creek Group, LP | 81,568 | $106.0K | 0.01% | 00.0% | Unchanged |
| Sigma Planning Corp | 203,900 | $265.1K | 0.01% | +104,750+105.6% | Added |
| Vanguard Group Inc | 210,070 | $273.1K | 0.00% | +41,414+24.6% | Added |
| Stonegate Investment Group, LLC | 232,310 | $302.0K | 0.01% | 00.0% | Unchanged |
| Voss Capital, LLC | 338,019 | $439.4K | 0.06% | 00.0% | Unchanged |